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ABSTRACT: The bacterial sliding clamp (SC), also known as the DNA polymerase III β subunit, is an emerging 
antibacterial target that plays a central role in DNA replication, serving as a protein–protein interaction hub with a common 
binding pocket to recognize linear motifs in the partner proteins. Here, fragment-based screening using X-ray crystallography 
produced four hits bound in the linear-motif-binding pocket of the Escherichia coli SC. Compounds structurally related to the 
hits were identified that inhibited the E. coli SC and SC-mediated DNA replication in vitro. A tetrahydrocarbazole derivative 
emerged as a promising lead whose methyl and ethyl ester prodrug forms showed minimal inhibitory concentrations in the 
range of 21–43 µg/mL against representative Gram-negative and Gram-positive bacteria species. The work demonstrates the 
utility of fragment-based approach for identifying bacterial sliding clamp inhibitors as lead compounds with broad-spectrum 
antibacterial activity. 
  
INTRODUCTION 
The emergence of antibiotic-resistant bacteria has presented a great challenge to humanity1 with new classes of antibiotics 
acting on novel targets being urgently needed.2-4 The bacterial sliding clamp (SC), also known as the DNA polymerase III 
(Pol III) β subunit, is a torus-shaped homodimeric protein5 that is conserved across bacterial species.6-8 The SC serves as a 
protein–protein interaction (PPI) hub during bacterial DNA replication and repair,9, 10 surrounding double-stranded DNA and 
subsequently recruiting a diverse range of protein binding partners, including the δ and α subunits of DNA Pol III, DNA Pols 
I, II, IV, V and MutS.5, 9 The pivotal role it plays in bacterial DNA replication and repair, its conserved structure across 
bacterial species6-8 and its structural divergence from the equivalent human protein (proliferating cell nuclear antigen, 
PCNA)9, 11 make the SC a highly attractive target for producing new antibiotics acting via a novel mechanism.  
Proteins that interact with the SC recognise a surface binding pocket that consists of two subsites (I and II),6, 12, 13 with one 
pocket located on each of the SC monomers (Figure 1). These protein binding partners interact with the SC using linear 
motifs (LMs) located on their surfaces.5, 13, 14 LMs are short (4–10 residue), intrinsically disordered sequences most often 
found at the termini of proteins but sometimes in loop regions.15-17 Binding of LMs to rigid protein domains represents a 
distinct category of protein–protein interactions (PPIs) that generally display weak affinities (Kd ~ 1–100 µM).18-23 PPIs are 
attractive drug targets, but the development of small-molecule inhibitors is considered challenging due in part to the shape 
and large surface areas of such sites.24 Nevertheless, an increasing number of inhibitors of PPIs are being reported, with 
recent examples including inhibitors of clathrin,25 the polo-box domain of polo-like kinase 126 and 14-3-3 protein27.  
A consensus LM sequence QLx1Lx2F/L (S/D preferred at x1; x2 may be absent) has been identified that interacts with the 
SC LM-binding pocket, and isolated peptides based on this sequence have been shown to bind the SC (Figure 1A) with 
affinities similar to their parent proteins28-30 and, conversely, when LMs are removed from the parent proteins, they lose all 
SC affinity.13, 31 Our recent work proposed a mechanism of sequential binding of LMs to the E. coli SC and highlighting the 
role of subsite I as the “anchor site” for LM recognition.30 Two classes of small molecules have previously been reported that 
bind to subsite I (Ki >10 µM), but no antibacterial activities were provided for these compounds.12, 28  
 
Figure 1. (A) X-ray crystal structures of consensus pentapeptide AcQLALF bound to the E. coli SC (PDB entry 4K3P30). The complex is 
shown with the SC colored orange and the peptide carbon atoms light green. All other atoms are presented in CPK colors. Dashed lines in 
red represent H-bonds. (B) Stereo view of the SC binding pocket (PDB entry 4K3S30 chain A). SC carbon atoms are shown shaded white. 
All other atoms are presented in CPK colors. Electrostatic potential surfaces of the binding site are shown with blue = positive and red = 
negative. A crystallographic water molecule is shown as a red sphere; arrows indicate the deep (red) and shallow (green) regions of subsite 
I in A and B. 
In this work, X-ray crystallography was used as a primary screen to identify fragment hits against the E. coli SC. Binding 
poses adopted by these hits were used in combination with chemo-informatics to guide subsequent inhibitor design, with 
several promising compounds being identified that bind to the SC, disrupt LM–SC interactions and inhibit SC-dependent 
DNA replication in vitro. Anti-bacterial activity was demonstrated for a lead inhibitor against two Gram negative and two 
Gram positive bacterial species. 
RESULTS 
Fragment-Based Screening Using X-Ray Crystallography. A total of 352 fragment compounds from the First Pass 
Screen (Zenobia Fragment Libraries) were soaked into E. coli SC crystals as 4-in-1 cocktails and screened using X-ray 
crystallography. Four fragment hits showing good electron density: 3,4-difluorobenzamide 1, 5-chloroisatin 2, 6-
nitrobenzopyrazole 3 and 5-nitroindole 4, were found to bind in subsite I of the binding pocket on Chain A of the SC dimer 
(complexes denoted as SC1, SC2, SC3 and SC4, respectively, in Figure 2; crystallographic data are in Table S1, Supporting 
Information). No significant changes in the SC main-chain structure were observed upon fragment binding. Several other 
fragments were identified that bind in subsite I but they showed only weak electron density and were not investigated further. 
An additional six fragments were identified that bound only in the binding pocket of chain B, where they were stabilized by a 
symmetry-related protein molecule. These were considered to be crystallographic artefacts and were not pursued.  
 
Figure 2. X-ray co-crystal structures showing binding of fragment hits 1–4 to subsite I of the E. coli SC LM-binding pocket. The 
complexes denoted (A) SC1, (B) SC2, (C) SC3 and (D) SC4 are shown with the SC carbon atoms colored orange and the bound fragment 
carbon atoms light green. All other atoms are presented in CPK colors. Apo-SC structures (PDB entry 4K3S30 chain A) are superimposed 
on the SC structures in the complexes for comparison (shown in white). Hydrogen bonds from S346 to fragment nitro-groups are 
represented as dashed red lines. Electron density maps (2mFo–DFc) contoured at 1 σ are shown in blue wire-basket form. 
The four fragment hits bound in the deep region of subsite I forming van der Waals’ interactions with the hydrophobic side 
chains of V360, V247, L177 and M362 (Figure 2). The shallow region of subsite I, comprising residues T172, P242 and 
L155, remained vacant (Figures 1B and 2). Each fragment positioned an aromatic ring in the narrow groove of subsite I with 
the fluoro and chloro substituents of 1 and 2 being buried in the deep hydrophobic region (Figure 2A,B). Binding of both 1 
and 2 caused rotation of the side chain of S346 relative to the apo-SC structure. Fragments 3 and 4 bound in a similar manner 
to 1 and 2 placing their NO2 groups in the positions occupied by the halogen atoms of 1 and 2 (Figure 2C,D). The NO2 
groups appeared to accept H-bonds from the side-chain of S346, allowing this residue to retain the same conformation it 
adopts in the apo-SC structure.30 
A fluorescence polarization (FP)-based competition assay was used to quantify inhibition of a LM–SC interaction by the 
four fragment hits.30 In this assay, a fluorescently labeled SC-binding tracer peptide based on a LM derived from the 
consensus-binding motif (5-carboxyfluorescein-QLDLF, Kd = 70 nM)12, 32, 33 was used as the competitive probe ligand. 
Inhibition of tracer binding to the E. coli SC was plotted against inhibitor concentrations and IC50 values were calculated and 
transformed into inhibition constants (Ki) using the Kenakin correction for ligand depletion.34 None of the four hits 1–4 
showed any significant inhibition of probe binding below 1 mM under the assay conditions (data not shown). 
Identification of Fragments That Fully Occupy Subsite I. Following identification of fragment hits 1–4, we sought to 
improve binding affinity by identifying fragments that could more completely occupy subsite I, including the shallow region. 
It was noted that the fluoroaryl ring found in 1 was also present in the previously reported biphenyl inhibitor28, triggering 
further investigations with compound 5,a readily available analogue containing the fluorobiphenyl moiety (Table 1). A Ki of 
280 µM was measured for 5 using the FP assay30 (Table 1) and its X-ray co-crystal structure was solved in complex with the 
SC (denoted SC5). Compound 5 was found to fully occupy subsite I (Figure 3A; crystallographic data in Table S2, 
Supporting Information), with its fluoroaryl ring adopting a similar binding pose to that of 1. The side-chain of M362 was 
observed to rotate toward subsite II, possibly due to steric crowding. The second phenyl ring of 5 occupied the shallow region 
of subsite I, with its carboxylate group involved in a salt bridge and/or H-bonds with the side chains of R152 and Y154. Both 
of these side chains move slightly toward the carboxylate of 5 relative to their positions in the apo-structure. 
The ZINC library35 was subsequently searched for compounds displaying structural similarity to fragments 1–5. Selected 
molecules were subjected to a docking-based screen using UCSF DOCK6.536 and candidates were purchased for screening 
using the FP assay. Initial efforts failed to yield hits with Ki < 1 mM but it was noted during the work that 5-chlorocarbazoles 
appeared promising. Further searches of the ZINC library35 identified several 5-chlorocarbazoles including 6, which showed 
a Ki of 199 µM (Table 1 and Table S3, Supporting Information). The X-ray co-crystal structure of 6 was obtained, but the 
compound, although clearly binding in subsite I, showed only weak electron density (data not shown). 
The slight curvature at the base of subsite I (due to P242) appeared likely to impair binding of rigid/planar compounds like 
6 and it was postulated that ligands with increased flexibility might better complement the curvature. Searches of the ZINC 
library35 (Table S3, Supporting Information) identified tetrahydrocarbazoles 7 and 8, which were found to have Ki values of 
216 and 64 µM, respectively (Table 1). Compounds 9 and 10, the methyl and ethyl esters of 8, displayed significantly weaker 
binding, highlighting the importance of the acid group. Eighteen additional tetrahydrocarbazoles were synthesized and 
evaluated using the FP assay but all showed poor SC binding affinities (11–29, Table S3 and Scheme S1, Supporting 
Information). 
The X-ray co-crystal structures of 7 and 8 in complex with the E. coli SC were solved (denoted as SC7 and SC8 in Figure 
3B,C; crystallographic data in Table S2, Supporting Information). Compounds 7 and (R)-8 were both found to completely 
occupy subsite I with their tetrahydrocarbazole rings nestled against P242. Binding of 7 preserved the position of all residues 
in subsite I and had no effect on the overall protein structure. The carboxylate group of 7 made two H-bonds to the backbone 
carbonyl oxygen atom of V247 and the hydroxyl group of S346. Interestingly, while the commercially obtained carboxy-5-
chlorotetrahydrocarbazole 8 was racemic only the (R)-enantiomer appeared in the electron density map (Figure 3C). The 
binding of (R)-8 caused conformation changes in the M362 and S346 side chains relative to the apo-structure and buried the 
5-chloro group in the hydrophobic deep region of subsite I. The carboxyl group of 8 appeared to interact with the 
guanidinium group of R152, which may explain the preference for binding of the (R)-enantiomer in the crystal.  
Ligand efficiency (LE) and ligand lipophilicity efficiency (LLEAT)37 were calculated (Supporting Information) to assess the 
suitability of these fragments for further medicinal chemistry optimization (Table 1), where it is considered that compounds 
with LE and LLEAT values greater than 0.3 are desirable.37 Compounds  7 and 8 showed LLEAT values > 0.4 suggesting they 
are attractive scaffolds for further optimization.  
  
Table 1. Follow-up Fragment Inhibitors of the E. coli SC Identified from Initial Hits 1–4 
n/a: not available  
Figure 3. X-ray co-crystal structures of 5, 7 and 8 bound to subsite I of the E. coli SC LM-binding pocket. Complexes are denoted (A) SC5, 
(B) SC7, (C) SC8 and are shown with the SC carbon atoms colored orange and the ligand carbon atoms light green. All other atoms are 
presented in CPK colors. Apo-SC structures (PDB entry 4K3S30 Chain A in B and 1MMI38 Chain A in A and C) are superimposed (shown 
in white) on the SC structures of the complexes for comparison. H-bonds are represented as dashed red lines. Electron density maps 
(2mFo–DFc) contoured at 1 σ are shown in blue wire-basket form. 
  
Compound Structure 
IC50 
(µM) 
Ki 
(µM) 
LE 
(kcal/mol) 
LogD 
(pH 7.2) 
LLEAT 
5  504 280 0.3 –3.17 0.22 
6 
 
358 199 0.28 –4.93 0.12 
 
Compound R1 R2 R3 R4 Ring A 
IC50 
(µM) 
Ki 
(µM) 
LE 
(kcal/mol) 
LogD 
(pH 7.2) 
LLEAT 
7 H Cl CO2H H cyclohexyl 389 216 0.3 –0.48 0.45 
8 H Cl H H 1-CO2H cyclohexyl 115 64 0.34 0.36 0.42 
9 H Cl H H 1-CO2Me cyclohexyl > 1000 n/a n/a n/a n/a 
10 H Cl H H 1-CO2Et cyclohexyl ~ 899 ~ 499 0.24 4.44 0.03 
Two E. coli SC inhibitors, a thioxothiazolidinyl derivative RU7 12 and a biphenyloxime ether derivative,28 have previously 
been identified that bind to the subsite I. Their binding poses are compared with that of (R)-8 in Figure S1 (Supporting 
Information). It is noteworthy that when superimposed, the aryl ring systems of all three compounds are approximately co-
planar and project their halogens into the deep region of subsite I (Figure 1B). While all three compounds show low-
micromolar affinity, RU7 and the biphenyloxime ether derivative project large moieties towards bulk solvent that appear to 
contribute few (if any) binding interactions. In the case of RU7, the thiocarbonyl and carboxymethyl moieties are oriented 
toward solvent while the biphenyloxime ether derivative projects its substituted cyclohexyl moiety toward the solvent. 
Compound (R)-8, on the other hand, projects no groups out into the solvent and better complements the geometry of subsite I, 
thus suggesting it is a more suitable lead for optimization studies. 
E. coli SC Inhibitors Disrupt in vitro DNA Replication and show Antibacterial Effects. An in vitro DNA replication 
assay was used to assess inhibition of E. coli SC function by compounds 5–8. The reaction system contained the SC, Pol III α 
subunit and the reconstituted clamp loader complex (γ3δδ').39 During E. coli replication the SC is loaded onto DNA by the 
clamp-loader complex (composed minimally of Pol III δ, γ/τ and δ’ subunits)40-42 and confers high processivity upon the Pol 
III α subunit (the replicase) by acting as a mobile tether.43, 44 Circular single-stranded M13 DNA (ssDNA) with an annealed 
RNA primer was used as the template for DNA synthesis and was coated with single-stranded DNA-binding protein (SSB). 
The SC is loaded onto the primed DNA by the clamp loader complex and the α subunit (bound to the SC) catalyzes extension 
of the primer through incorporation of dNTPs using ssDNA as a template. A schematic illustration of this assay is shown in 
the Supporting Information (Figure S3). 
With this assay system, binding of the DNA Pol III δ and α subunits to the SC is essential for replication, meaning 
impaired SC binding due to the presence of inhibitors will hinder DNA synthesis, as shown by the presence of ssDNA 
templates and incomplete dsDNA products. A complete dsDNA product is formed when the whole of the ssDNA circle is 
replicated (see Figure S4, Supporting Information for control experiment). Compounds 5, 6 and 7 were found to inhibit 
replication at 500 or 1000 µM (Figure 4A–C), while compound 8 produced complete inhibition at 250 µM (Figure 4D), 
consistent with its higher SC affinity (Table 1). 
 
Figure 4. Inhibition of SC-dependent in vitro DNA synthesis by 5 (A), 6 (B), 7 (C) and 8 (D). Ladders on the left show molecular size 
markers. Circles with a dash above represent primed ssDNA templates and concentric circles represent fully replicated dsDNA product. 
The antibacterial effects of compounds 5, 7–10 were carried out against two representative Gram-negative (E. coli and A. 
baylyi) and two Gram-positive (B. subtilis and S. aureus) species. The background-corrected optical density was measured 
after 24 hours of bacterial growth (Table S4, Supporting Information). The minimum inhibitory concentrations (MICs), 
defined as the background-corrected optical densities of less than 0.1, are shown in Table 2. Compounds 5 and 7 showed only 
slight antibacterial activity (MICs 540 to 1246 µg/mL), consistent with their modest E. coli SC-binding affinities (Table 1). 
Their carboxylic acid groups may have reduced membrane penetration. The MIC of 8 (39–78 µg/mL) was lower than 5 and 7 
against all four species, consistent with its higher SC affinity (Table 1). Compounds 9 and 10 were considered as possible 
prodrug forms of 8 (i.e., methyl and ethyl esters, respectively) that might show improved membrane penetration properties. 
Esters 9 and 10 displayed increased antibacterial activity relative to 8 (MICs 21–43 µg/mL) despite having lower affinities 
for the SC (Table 1), consistent with their acting as membrane permeable prodrugs. 
  
Table 2. Antibacterial Activities of Compounds 5–10 
Compound 
Minimum inhibitory concentration (MIC) 
E. coli A. baylyi B. subtilis S. aureus 
µM µg/mL µM µg/mL µM µg/mL µM µg/mL 
5 2500 540 5000 1080 2500 540 5000 1080 
7 2500 623 5000 1246 2500 623 2500 623 
8 313 78 313 78 156 39 156 39 
9 156 41 78 21 78 21 156 41 
10 78 22 156 43 78 22 78 22 
n/a: not available 
DISCUSSION 
PPIs are often considered difficult targets to inhibit with small molecules.45 Nevertheless, several PPI inhibitors have been 
successfully developed.46 Studies indicate that PPIs rely on so-called “hotspots” for most of the interaction energy and, 
accordingly, these are usually the most productive sites for inhibitor design.24 We previously identified subsite I as the 
“anchor site” of consensus peptide binding to the E. coli SC, indicating that this site acts as the SC “hotspot”.30 We also 
showed that the affinity of peptide LMs for the E. coli SC arises from residues occupying both subsites I and II,30 suggesting 
that the potential of these individual subsites as drug targets is probably limited. The close proximity of the two subsites, 
however, suggests that fragment-based approaches are highly suited to identifying inhibitors of this target. 
Fragment screening in the current work using X-ray crystallography initially identified four hits, but these proved to be 
weak binders (Ki >1 mM). The high sensitivity of X-ray crystallography and its ability to identify weak binders in fragment-
based screening efforts has previously been noted.47  
All four hits were found to bind in subsite I, i.e., the LM “anchor site”.30 Follow-up investigations led to the identification 
of several SC-binding ligands with the substituted tetrahydrocarbazole 8 showing the highest SC affinity (Ki = 64 µM) and 
excellent ligand lipophilicity efficiency (LLEAT = 0.42). Tetrahydrocarbazoles 7 and 8 were shown by crystallography to bind 
in subsite I and to inhibit in vitro DNA replication. Although compound 8 showed antibacterial activity (MICs 39–78 µg/mL) 
against representative bacteria, these effects were improved upon masking the carboxylic acid as methyl and ethyl ester 
prodrugs (compounds 9 and 10, MICs 21–43 µg/mL). In this study the X-ray crystallography screening, and FP and in vitro 
DNA replication assays were all carried out using the SC from E. coli, yet similar antibacterial potencies were observed with 
compounds 9 and 10 against E. coli, A. baylyi, B. subtilis and S. aureus. This finding is consistent with the high conservation 
of SC structure across bacterial species6 and suggests that the E. coli SC serves as an excellent model system for identifying 
SC inhibitors that could potentially be developed into broad-spectrum antibiotics. 
Current work in our laboratories aims to improve the SC affinities of the tetrahydrocarbazoles by targeting both subsite I 
and II. Our previous work suggested that residues of peptide ligands occupying subsite II contribute significantly to the 
binding affinity and that binding at subsite II is subsequent to binding at subsite I (the “anchor site”).30 A conformational 
change in the side chain of M362 was proposed to act as a gate in the channel region connecting subsite I and II. 30 A similar 
conformational change in M362 was observed with the binding of (R)-8 in subsite I (Figure 3C). Therefore the synthesis of 
tetrahydrocarbazole derivatives substituted at the nitrogen atom may expand the inhibitor-binding area beyond subsite I, into 
the channel region and subsite II.  
Materials and Methods 
Compounds. Fragment compounds (including 1–4) were purchased from Zenobia Therapeutics (First-Pass Screen library). 
Compounds 5–10 and 6a–c were purchased from Sigma-Aldrich, Labotest, Enamine or Vitas-M Laboratory. Purchased 
compounds were ≥ 95% pure as confirmed by proton NMR and/or LC-MS. Compounds 11–29 (Table S3, Supporting 
Information) were synthesized in house (Scheme S1, Supporting Information). 
Protein Over-expression and Purification. Expression and purification of the E. coli SC, Pol III α subunit, SSB and the 
clamp loader complex (γ3δδ’) were as described previously.29, 38, 39, 48 
Crystallization and X-Ray Data Collection. Crystals of the E. coli SC were grown at 285 K by the hanging-drop vapor 
diffusion method. The drop was composed of 1 µL of sliding clamp (53 mg/mL) mixed with the same volume of reservoir 
solution of 100 mM MES pH 6.5, 100–150 mM CaCl2 and 25–30% (v/v) PEG400. The reservoir volume was 1 mL. SC 
crystal were moved to a CaCl2-free reservoir and ligands were soaked into the crystal at 2–5 mM with < 10% DMSO. 
Fragment compounds were mixed as 4-in-1 cocktails as suggested by the supplier and soaked into crystals with each 
fragment at 5 mM. All crystals were mounted using MiTeGen™ loops on pins with magnetic caps. For in-house data 
collection crystals were flash-frozen at 100 K using an Oxford Cryo-stream. Diffraction data were collected using a MAR345 
desktop beamline using CuKα X-rays from a Rigaku 007HF rotating anode generator with Varimax™ optics. For 
synchrotron data collection, the SSRL Automated Mounting system (SAM) was used. Mounted crystals were flash-frozen in 
liquid nitrogen and diffraction data were collected at the Australian Synchrotron, Beamline MX1 (X-ray wavelength 0.95 Å) 
using Blu-Ice.49 
Data Processing, Structure Solution and Refinement. Crystal data sets were integrated, merged and scaled with either 
HKL200050 or MOSFLM and SCALA.51 The structures were solved by molecular replacement with CCP4 using the Protein 
Data Bank entry 1MMI or 4K3S as the starting model. Iterative cycles of model building and refinement were performed in 
COOT52 and REFMAC5.53 
Fluorescence Polarization Assay. FP experiments were carried out according to the published protocol.30 
Molecular Docking and Chemoinformatics. Details are in Supporting Information. 
Antibacterial Activity. Determination of minimum inhibitory concentrations (MICs) were carried out with bacterial 
strains Escherichia coli DH5α, Acinetobacter baylyi ADP1, Bacillus subtilis SU5 and Staphylococcus aureus NCTC8325. 
Experiments followed the CLSI broth microdilution method.54 Briefly, strains were grown overnight and diluted to 5 x 104 
CFU/mL with cation-adjusted Mueller Hinton II broth and used as inoculated medium for bacterial growth. Serial 2-fold 
dilution of candidate compounds (pre-dissolved in DMSO at 100 mM) or antibiotics were carried out in sterile 96-well plates. 
Controls consisted of the growth medium only (blank controls) or inoculated medium with 5% DMSO or DMSO diluted as 
for the test compounds (negative controls), and inoculated medium with antibiotics (positive controls). Optical density values 
of each inoculated culture were measured at wavelength 595 nM as the background using a plate reader (Tecan Infinite M200 
Pro). The plates were incubated for 24 h at 37°C and then the optical density values of the bacterial culture were measured 
again. MICs were defined as the lowest compound concentration with background-subtracted optical density < 0.1. 
DNA replication assay. Each assay contained 20 mM Tris-HCl pH 7.6, 10 mM MgCl2, 0.8 mM ATP, 8.4 mM 
dithiothreitol, 0.6 mM of each dNTP, 211 nM Pol III α subunit, 700 nM SSB (as tetramers), 210 nM Pol III β subunit (as 
dimers), 42 nM γ3δδ’ clamp loader complex, 120 mM NaCl and 3 nM RNA primed M13 ssDNA template, in a volume of 6.8 
µL. Compounds were dissolved in DMSO and diluted in series 2-fold (in 50% v/v DMSO) before being added (0.5 µL) to the 
assay mixture at 0°C. The final DMSO concentration was 3.4% (v/v) in all assays. The assay mixtures were treated at 30°C 
for 60 min before being quenched by the addition of EDTA to 150 mM and SDS to 1% (w/v). The DNA products were 
separated by 0.7% agarose gel electrophoresis in TAE buffer (80 mM Tris, 40 mM acetic acid, and 4 mM EDTA) and then 
stained with 10,000-fold diluted SYBR Gold (Invitrogen) for 60 min. The DNA products were visualized using a UV 
transilluminator. 
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Table S1. Data collection and refinement statistics for X-ray co-crystal structures of the E. coli SC in 
complex with fragment hits 1–4 (i.e. complexes SC1 – SC4, respectively). 
Name SC1 SC2 SC3 SC4 
PDB Code 4N94 4N95 4N96 4N97 
Data collection  
Space group P1 P1 P1 P1 
Cell dimensions 
a, b, c (Å) / α, β, γ (°) 
40.74, 64.51, 71.72 / 
74.01, 83.21, 84.54 
a, b, c (Å) / α, β, γ (°) 
40.99, 65.51, 73.44/ 
73.03, 85.29, 85.65 
a, b, c (Å) / α, β, γ (°) 
40.88, 64.67, 72.02 / 
73.97, 83.55, 84.36 
a, b, c (Å) / α, β, γ (°) 
40.88, 64.78, 72.59 / 
73.91, 84.51, 84.89 
Resolution (Å) 30.38–1.73(1.82–1.73) 28.86–1.80 (1.90–1.80) 30.51–1.70 (1.79–1.70) 28.9–1.97 (2.08–1.97) 
Rmerge (%) 6.7 (55.1) 6.4 (39.9) 4.8 (32.8) 5.6 (19.1) 
No. of Reflections 242483 235693 242187 153662 
Unique 
Reflections 
66608 (8933) 61187 (8833) 64167 (9074) 42650 (6264) 
Mean I/σ(I) 9.9 (2.1) 14.3 (3.2) 15.2 (3.4) 12.7 (6.4) 
Completeness 
(%) 
91.7 (84.2) 95.9 (94.7) 83.0 (80.4) 84.8 (85.2) 
Multiplicity 3.6 (3.6) 3.9 (3.8) 3.8 (3.7) 3.6 (3.3) 
Refinement  
Resolution (Å) 28.91–1.73 (1.78–1.73) 28.32–1.80 (1.85–1.80) 28.72–1.70 (1.74–1.70) 28.9–1.97 (2.02–1.97) 
Rwork/Rfree (%) 25.1 (35.5)/29.2 (44) 18.6 (26.4)/22.4 (30.3) 22.7 (33.2)/27.5 (42.0) 23.2 (30.9)/30.6 (42.7) 
R.m.s deviations     
Bond lengths (Å) 0.0098 0.0068 0.0083 0.0077 
Bond angles (º) 1.4687 1.2819 1.3235 1.3011 
B-factors     
M. Chain 20.6 18.5 19.3 20.25 
S. Chain & Water 24.2 23.3 22.6 22.89 
Ligands* 41.5 49.7 26.6 35.1 
Ramachandran 
Plot Outliers 
0.57% 0.44 % 0.58 % 0.58 % 
Values for data in the highest resolution shell are given in parentheses. 
Diffraction data were collected at Beamline MX1, Australian Synchrotron, at a wavelength of 0.95 Å. Diffraction 
data were processed with MOSFLM and SCALA. 
*Ligands refer to the fragment compounds bound to Chain A.
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Table S2. Data collection and refinement statistics for X-ray co-crystal structures of the E. coli 
SC in complex with compounds 5, 7 and (R)-8 (i.e. complexes SC5 – SC7 and SC8, 
respectively). 
Name SC5 SC7 SC8 
PDB Code 4N98 4N99 4N9A 
Data collection 
Space group P21 P1 P21 
Cell dimensions 
a, b, c (Å) / α, β, γ (°) 
79.90, 67.16, 81.06 / 90.00, 
114.11, 90.00 
a, b, c (Å) / α, β, γ (°) 
41.01, 65.13, 73.24 / 
72.95, 85.06, 85.24 
a, b, c (Å) / α, β, γ (°) 
79.78, 67.37, 81.12 /       
90.00, 113.92, 90.00 
Resolution (Å) 30.50–1.70 (1.79–1.70) 40.95–2.30 (2.42–2.30) 43.86–1.90 (2.00–1.90) 
Rmerge (%) 9.7 (68.3) 14.7 (64.3) 5.2(39.7) 
No. of Reflections 603665 112766 137425 
Unique Reflections 86092 (12490) 29744 (4227) 57937 (7647) 
Mean I/σ(I) 9.2 (2.4) 8.5 (2.2) 9.8 (2.4) 
Completeness (%) 99.9 (99.8) 92.9 (89.9) 93.7 (85.6) 
Multiplicity 7.0 (6.9) 3.8 (3.7) 2.4 (2.3) 
Refinement 
Resolution (Å) 30.17–1.70 (1.74–1.70) 40.95–2.30 (2.36–2.30) 36.46–1.90 (1.95–1.90) 
Rwork/Rfree (%) 25.6 (30.0)/29.6 (35.5) 26.1 (32.1)/33.7 (42.9) 21.4 (38.8)/26.1( 40.7) 
R.m.s. deviations    
Bond lengths (Å) 0.0079 0.0042 0.0090 
Bond angles (º) 1.2817 0.8770 1.3791 
B-factors    
M. Chain 22.3 21.0 28.1 
S. Chain & Water 26.4 23.1 33.2 
Ligands* 39.8 51.7 42.1 
Ramachandran Plot 
Outliers 
0.58% 0.56 % 0.72 % 
Values for data in the highest resolution shell are given in parentheses. 
Diffraction data for SC5 were collected at Beamline MX1, Australian Synchrotron, at a wavelength of 
0.95 Å.  
Diffraction data for SC7 and SC8 were collected using an in-house X-ray generator (University of 
Wollongong) at a wavelength of 1.5418 Å. 
Diffraction data were processed with MOSFLM and SCALA. 
*Ligands refer to the compounds bound to Chain A. 
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Table S3: Binding data for carbazole and tetrahydrocarbazole derivatives against the E. coli 
SC. 
 
cpd R1 R2 
IC50 
(µM) Ki (µM) 
LE 
(kcal/ 
mol) 
LogD 
(pH 7.2) LLEAT 
6a H 
 
> 1000 n/a n/a n/a n/a 
6b H 
 
885 492 0.16 4.41 0.06 
6c H 
 
> 1000 n/a n/a n/a n/a 
 
cpd R1 R2 R3 R4 ring A 
IC50 
(µM) 
Ki 
(µM) 
LE  
(kcal/ 
mol) 
LogD 
(pH 
7.2) 
LLEAT 
11 H H H Cl 3-CO2Me cyclohexyl 851 473 0.25 3.91 0.07 
12 H Cl CO2H H cycloheptyl 877 487 0.25 –0.16 0.38 
13 H CO2H Cl H cyclohexyl > 1000 n/a n/a n/a n/a 
14 Cl CO2H H H cyclohexyl > 1000 n/a n/a n/a n/a 
15 H Cl H H 3-CO2Et cyclohexyl > 1000 n/a n/a n/a n/a 
16 H Cl H H 3-CO2H cyclohexyl > 1000 n/a n/a n/a n/a 
17 H Cl H H 3-CO2Me cyclohexyl > 1000 n/a n/a n/a n/a 
18 H Cl H H cyclopentyl > 1000 n/a n/a n/a n/a 
19 H Cl H H 3-piperidinyl > 1000 n/a n/a n/a n/a 
20 H Cl H H cycloheptyl > 1000 n/a n/a n/a n/a 
21 Cl H H H 1-CO2Me cyclohexyl > 1000 n/a n/a n/a n/a 
22 H H H Cl cyclohexyl > 1000 n/a n/a n/a n/a 
23 H H H Cl 3-CO2Et cyclohexyl > 1000 n/a n/a n/a n/a 
24 H H H Cl 3-CO2H cyclohexyl > 1000 n/a n/a n/a n/a 
25 H Cl OH H cyclohexyl > 1000 n/a n/a n/a n/a 
26 CO2H Cl H H 2-CO2H cyclohexyl > 1000 n/a n/a n/a n/a 
27 CO2H Cl H H cyclopentyl > 1000 n/a n/a n/a n/a 
28 CO2H Cl H H cycloheptly > 1000 n/a n/a n/a n/a 
29 H Cl CO2Me H cyclohexyl > 1000 n/a n/a n/a n/a 
n/a: not applicable 
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Figure S1. Inhibition of binding of a fluorescently labelled tracer peptide (5FAM-QLDLF) to the 
E. coli SC. Data are standardized and shown as inhibition (%, decreased polarization divided by 
background subtracted total polarization). Error bars represent standard deviation (n=2). 
 
 
	  
	  
 
Scheme S1. Synthesis of substituted tetrahydrocarbazoles 11–29. Reagents: (a) AcOH or 
EtOH and HCl (cat)), ketone, reflux, 3–64%; (b) i) AcOH, ketone, reflux, ii) MeOH, H2SO4 (cat.) 
reflux, 18%; (c) i) NaOH, EtOH, rt., ii) MeOH, H2SO4 (cat.) reflux, 44%; (d) NaOH, EtOH, rt, 31–
47%; (e) MeOH, H2SO4 (cat.) reflux, 65%. 
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Figure S2. Stereo diagrams of (A) (R)-8, (B) RU7 reported by Georgescu et al.1	  and (C) a 
biphenyloxime ether derivative reported by Wijffels et al.2 binding to subsite I of the E. coli SC 
LM-binding pocket. Carbon atoms of the inhibitors are colored light green and the SC carbon 
atoms are colored orange. Other atoms are in CPK colors. 
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Figure S3. Schematic representation of the in vitro DNA replication assay. 
 
 
 
Figure S4. In vitro DNA replication control assay carried out in the presence of 3.5% DMSO (no 
inhibitor). Molecular sizes (in bp for dsDNA) corresponding to bands in the DNA ladder are 
shown. Circles with a dash represent primed ssDNA template. Concentric circles represent 
dsDNA replication products. 
  
	  
	  
8	  
Table S4: Optical density (absorbance at 595 nM) measured for 24h bacterial growth under 
varying compound concentrations.* 
*Optical density values are subtracted of the background. 
  
E. coli Compound concentration (µM) 
Compd. 5000 2500 1250 625 312.5 156.25 78.13 39.06 19.53 9.77 4.88 2.44 
5 -0.11 0.05 0.12 0.15 0.20 0.13 0.20 0.17 0.13 0.15 0.14 0.14 
7 0.01 0.07 0.20 0.17 0.18 0.16 0.14 0.11 0.14 0.14 0.12 0.17 
8 -0.57 -0.29 -0.08 -0.04 -0.01 0.16 0.15 0.24 0.12 0.14 0.15 0.18 
9 -0.02 -0.03 -0.08 -0.06 -0.04 -0.02 0.16 0.15 0.15 0.13 0.12 0.17 
10 -0.35 -0.15 -0.14 -0.11 -0.09 0.02 0.03 0.13 0.12 0.15 0.15 0.17 
A. baylyi Compound concentration (µM) 
Compd. 5000 2500 1250 625 312.5 156.25 78.13 39.06 19.53 9.77 4.88 2.44 
5 -0.20 0.31 0.42 0.44 0.49 0.39 0.39 0.38 0.46 0.45 0.46 0.39 
7 0.01 0.19 0.37 0.46 0.52 0.48 0.53 0.46 0.38 0.47 0.45 0.49 
8 -0.57 -0.28 -0.10 -0.03 0.07 0.34 0.39 0.39 0.38 0.39 0.48 0.45 
9 -0.07 -0.04 -0.01 0.07 0.03 0.04 0.04 0.39 0.40 0.41 0.41 0.45 
10 -0.28 -0.09 -0.09 0.01 0.01 0.03 0.37 0.39 0.39 0.43 0.39 0.45 
B. subtilis Compound concentration (µM) 
Compd. 5000 2500 1250 625 312.5 156.25 78.13 39.06 19.53 9.77 4.88 2.44 
5 -0.08 0.01 0.15 0.21 0.21 0.23 0.18 0.18 0.16 0.15 0.19 0.27 
7 0.00 0.08 0.11 0.13 0.16 0.20 0.23 0.24 0.24 0.24 0.22 0.21 
8 -0.33 -0.17 -0.04 -0.02 0.00 0.00 0.13 0.19 0.26 0.23 0.23 0.23 
9 0.01 -0.01 -0.05 -0.05 -0.03 -0.01 0.08 0.20 0.22 0.22 0.20 0.23 
10 -0.33 -0.10 -0.03 -0.04 -0.06 -0.04 0.07 0.15 0.18 0.19 0.22 0.21 
S. aureus Compound concentration (µM) 
Compd. 5000 2500 1250 625 312.5 156.25 78.13 39.06 19.53 9.77 4.88 2.44 
5 -0.09 0.13 0.20 0.17 0.18 0.19 0.19 0.22 0.21 0.17 0.22 0.23 
7 0.00 0.07 0.12 0.16 0.19 0.15 0.18 0.17 0.18 0.14 0.17 0.21 
8 -0.35 -0.17 -0.01 -0.02 0.00 0.00 0.10 0.15 0.17 0.22 0.18 0.21 
9 0.00 -0.01 -0.05 -0.05 -0.03 0.05 0.18 0.21 0.27 0.23 0.21 0.23 
10 -0.32 -0.09 -0.02 -0.04 -0.06 -0.04 0.04 0.19 0.17 0.22 0.23 0.22 
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Supplementary Methods  
Molecular Docking and Chemo-Informatics. Fragment scaffolds were used for similarity and/ 
or substructure searches in the UCSF ZINC library.3 A number of larger scaffolds were used for 
substructure search of commercially available compounds for molecular docking using UCSF 
DOCK 6.5.4 The receptor was prepared by removing all crystallographic water molecules from 
the sidling clamp except for a structurally conserved water molecule near residue M362. 
Residues greater than 15 Å away from the binding pocket were deleted. Hydrogen atoms were 
added and partial charges were assigned. Ligands were prepared using UCSF Chimera or 
downloaded from UCSF ZINC library. Spheres for ligand orientations were generated using the 
identified fragment binders. A grid map for scoring was generated encompassing residues 
within 15 Å of the spheres. Docking was carried out using Grid score as the primary score and 
GB/SA Hawkins score as a secondary scoring method. The top 50 poses were clustered and 
the top 10 cluster heads assessed using the secondary scoring method. Additionally, Amber 
scoring5 was performed with 100 steps of minimization, 3000 md cycles and another 100 
minimization steps, each step corresponded to 2 fs. In all cases ligand flexibility was allowed 
and the receptor kept rigid. Selected molecules were acquired for testing. 
Calculation of LogD values at pH 7.2 was performed using Accord for Excel 6.2 (Accelrys). 
The equations used to determine LE and LLEAT followed the published methods6 and are 
detailed below: 
LE = –∆G/HAC 
      = –RTln(Ki)/HAC 
∆G* = ∆G – ∆Glipo 
        = RTln(Ki) + RTLogD 
LLEAT = 0.11 – ∆G*/HAC 
LE: ligand efficiency; ∆G: delta Gibbs energy; Ki: inhibition constant; HAC: heavy atom count; 
logD: distribution coefficient at pH 7.2; LLEAT: ligand lipophilicity efficiency. 
Organic Synthesis.1H and 13C NMR spectra were acquired on a Varian Mercury 300 MHz, 
Varian Inova 500 MHz or VNMRS 500 MHz spectrometer. Chemical shifts (δ) are reported in 
ppm relative to the solvent and coupling constants (J) are given in Hz. Electrospray (EI) LRMS 
were recorded on a Waters Micromass Platform LCZ spectrometer and HRMS were recorded 
on a Waters Xevo spectrometer, using an EI or ASAP source. Melting points were recorded 
using a Gallenkamp (Griffin) melting point apparatus and are uncorrected. Optical rotations for 
chiral compounds were measured on a Jasco P-2000 polarimeter. TLC was performed on 
precoated Merck silica gel 60 PF254 aluminium sheets and flash column chromatography (FCC) 
performed with Davisil silica gel (40–63 µm). Petrol refers to petroleum spirits of bp 40–60°C. 2-
chloro-4-hydrazinobenzoic acid hydrochloride (31) and 2-chloro-5-hydrazinobenzoic acid 
hydrochloride (32) were prepared as previoulsy reported by Green et al.7 (see general 
hydrazine formation procedure) from 2-chloro-4-aminobenzoic acid and 2-chloro-5-amino-
benzoic acid respectively. All final compounds have a purity of ≥ 95% by proton NMR. 
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General Fischer Indole Procedure. To a solution of the phenylhydrazine in glacial acetic acid 
(or absolute ethanol with HCl (cat.)) was added the ketone, and the resulting mixture refluxed 
for 2–17 h. The reaction mixture was cooled, concentrated and extracted with EtOAc (or 
CH2Cl2). The combined extracts were washed with water, brine, dried (MgSO4), concentrated 
and the residue purified by either recrystallisation or FCC.  
General Esterification Procedure. To a solution of the carboxylic acid in methanol (or 
ethanol), concentrated H2SO4 (cat.) was added and the solution refluxed for 2–23 h. The 
mixture was cooled, concentrated, neutralised with saturated NaHCO3 (aq) solution and 
extracted with CH2Cl2. The combined extracts were washed with brine, dried (MgSO4), 
concentrated and the residue purified by recrystallisation or trituration. 
General Deesterification Procedure. To a solution of the ester in absolute ethanol, sodium 
hydroxide (2 M) was added and the reaction mixture stirred at room temperature for 2–17 h. The 
reaction mixture was concentrated, diluted with water and washed with CH2Cl2. The aqueous 
layer was subsequently acidified with 1 M HCl and extracted with CH2Cl2. The combined 
extracts were washed with brine, dried (MgSO4) and concentrated. The residue was either used 
crude in subsequent reactions or purified by recrystallisation or trituration. 
General Hydrazine Formation Procedure. A suspension of the amine in concentrated HCl 
was stirred for 30 min in an ice/salt bath and then a cooled solution of NaNO2 in water added 
drop wise. The solution was stirred for 1 h and a cooled solution of SnCl.2H2O in concentrated 
HCl added drop wise. The suspension was allowed to warm to room temperature overnight and 
the resulting precipitate collected by vacuum filtration (washing with cold water then Et2O).  
Methyl 8-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate (11) 
General Fischer indole procedure with 2-chlorophenylhydrazine hydrochloride (310.3 mg, 1.73 
mmol) and ethyl-4-oxocyclohexane-1-carboxylate (268.1 mg, 1.58 mmol) provided ethyl 8-
chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate (23; 240.5 mg, 0.87 mmol, 55% yield) as 
a pale yellow crystalline solid following recrystallisation from methanol, mp 152 – 154 °C. 1H 
NMR (CDCl3, 500 MHz): 1.29 (3H, t, J = 7.5 Hz), 2.00-2.07 (1H, m), 2.30-2.32 (1H, m), 2.76-
2.92 (4H, m), 3.00 (1H, dd, J = 15.5 , 4.8 Hz), 4.20 (2H, q, J = 6.7 Hz), 7.00 (1H, t, J = 8.0 Hz), 
7.11 (1H, d, J = 8.0 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.98 (1H, s). 13C NMR (CDCl3, 125MHz): 14.4, 
22.4, 24.1, 25.8, 40.4, 60.6, 110.0, 116.1, 116.5, 120.2, 120.9, 129.2, 133.4, 134.0, 175.3. 
LRMS (ES+) m/z: 316.23 [M+K]+. HRMS (ES+) calcd. for C15H17NO2Cl [M+H]+ 278.0948, found. 
278.0948.     
General deesterification procedure with 23 (109.9 mg, 0.40 mmol), followed by general 
esterification procedure on the crude product in methanol provided 11 (46.0 mg, 44% yield) as 
an off-white crystalline solid following recrystallisation from methanol, mp 164 - 166°C.  1H NMR 
(CDCl3, 500 MHz): 2.01-2.08 (1H, m), 2.30-2.33 (1H, m), 2.80-2.93 (4H, m), 3.06-3.07 (1H, m), 
3.74 (3H, s), 7.00 (1H, t, J = 7.8 Hz), 7.12 (1H, d, J = 7.5 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.84 (1H, 
br s). 13C NMR (CDCl3, 125 MHz): 22.4, 24.0, 25.7, 40.2, 52.0, 109.8, 116.1, 116.5, 120.3, 
120.9, 129.1, 133.3, 134.0, 175.9. LRMS (ES-) m/z: 261.75 [M-H]-. HRMS (ES-) calcd. for 
C14H13NO2Cl [M-H]- 262.0635, found  262.0627. 
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9-chloro-1,2,3,4,5,6-hexahydrocyclohepta[b]indole-8-carboxylic acid (12) and 9-chloro-
1,2,3,4,5,6-hexahydrocyclohepta[b]indole-10-carboxylic acid (28) 
General Fischer indole procedure with 2-chloro-5-hydrazinobenzoic acid hydrochloride (32; 
487.1 mg, 2.18 mmol) and cycloheptanone (206.7 mg, 1.84 mmol) in glacial acetic acid (4 mL) 
produced a mixture of two isomers.  The two products were obtained following FCC on silica gel 
(gradient elution; 30:70:0.5-70:30:0.5 Et2O/petrol/acetic acid) and recrystallisation of each 
isomer from methanol/water. 12 (32.0 mg, 7% yield) was obtained as a beige powder, mp >250 
°C (dec.). 1H NMR (d6-DMSO, 300 MHz): 1.65-1.70 (4H, m,), 1.84 (2H, m), 2.70-2.74 (2H, m), 
2.82-2.86 (2H, m), 7.48 (1H, s,), 7.79 (1H, s), 11.21 (1H, s), 12.78 (1H, s). 13C NMR (d6-DMSO, 
75 MHz): 24.1, 26.9, 28.4, 28.7, 31.4, 112.6, 114.3, 18.7, 120.4, 122.2, 131.6, 131.8, 143.9, 
167.3. LRMS (ES-) m/z: 262.0 [M-H]-. HRMS (ASAP-) calcd. for C14H13NO2Cl [M-H]-262.0635, 
found 262.0626. 28 (12.3 mg, 3% yield) was obtained as a red/brown powder, mp 118 -120 °C.  
1H NMR (d6-DMSO, 500 MHz): 1.61-1.68 (2H, m), 1.67-1.68 (2H, m), 1.79-1.80 (2H, m), 2.66 
(2H, t like, J = 5.25 Hz), 2.80 (2H, t like, J = 5.5 Hz), 6.97 (1H, d, J = 8.5 Hz), 7.25 (1H, d, J = 
8.5 Hz), 11.12 (1H, s), 13.25 (1H, br s). 13C NMR (d6-DMSO, 75 MHz): 24.2, 26.7, 28.1, 28.2, 
31.2, 111.5, 112.4, 118.6, 119.6, 124.7, 124.8, 133.0, 141.6, 168.9. LRMS (ES-) m/z: 262.0 [M-
H]-. HRMS (ES-) calcd. for C14H13NO2Cl [M-H]- 262.0635, found 262.0642. 
7-chloro-2,3,4,9-tetrahydrocarbazole-6-carboxylic acid (13) and 5-chloro-2,3,4,9-
tetrahydrocarbazole-6-carboxylic acid (14)8 
General Fischer indole procedure with 2-chloro-4-hydrazinobenzoic acid hydrochloride (31; 
549.8 mg, 2.46 mmol) and cyclohexanone (300.6 mg, 3.06 mmol) in glacial acetic acid (3 mL) 
produced a mixture of two isomers. The two products were obtained following FCC on silica gel 
(gradient elution; 2:8–6:46 Et2O/petrol) and recrystallisation of each isomer from 
methanol/water. 13 (16.9 mg, 3% yield) was obtained as a beige powder, mp 248 – 250 °C. 1H 
NMR (MeOD, 500 MHz): 1.87-1.92 (4H, m), 2.68 (2H, d, J = 5 Hz), 2.72 (2H, d, J= 5.5 Hz), 7.31 
(1H, s), 7.97 (1H, s). 13C NMR (CDCl3+d6-DMSO, 125 MHz): 20.4, 22.6, 22.7, 22.9, 110.3, 
112.4, 119.5, 122.0, 125.6, 125.8, 136.5, 137.6, 168.5 (CO2H). LRMS (ES+) m/z: 272.2 [M+23]+. 
HRMS (ASAP+) calcd. for C13H13NO2Cl [M+H]+ 250.0635, found 250.0699. 14 (19.9mg, 3% 
yield) was obtained as a pink powder, mp 242 -244 °C. 1H NMR (CDCl3+d6-DMSO, 500 MHz): 
1.86 (4H, br s), 2.72 (2H, s), 3.11 (2H, s), 7.15 (1H, d, J = 8.5 Hz), 7.63 (1H, d, J = 8.5 Hz), 9.78 
(1H, br s). 13C NMR (CDCl3+d6-DMSO, 125 MHz): 22.3, 23.3, 23.4, 108.6, 111.1, 120.3, 123.8, 
125.9, 136.6, 138.3, 168.7. LRMS (ES-) m/z: 247.9 [M-H]-. HRMS (ES-) calcd for C13H11NO2Cl 
[M-H]- 248.0478, found. 248.0467.  
Ethyl 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate (15)9 
General Fischer indole procedure with 4-chlorophenylhydrazine hydrochloride (395.1 mg, 2.21 
mmol) and ethyl-4-oxocyclohexane-1-carboxylate (363.3 mg, 2.13 mmol) in absolute ethanol 
(5.5 mL) provided 15 (378.3 mg, 64% yield) as an off-white crystalline solid following 
recrystallisation from methanol, mp 134 -136 °C. 1H NMR (CDCl3, 500 MHz): 1.29 (3H, t, J = 
7Hz), 1.99-2.04 (1H, m), 2.28-2.30 (1H, m), 2.75-2.88 (4H, m), 3.00 (1H, dd, J = 15, 5.0 Hz), 
4.20 (2H, q, J = 7.2 Hz), 7.05 (1H, d, J = 8.5 Hz), 7.15 (1H, d, J = 8.5 Hz), 7.41 (1H, s), 7.81 
(1H, s). 13C NMR (CDCl3, 125MHz): 14.4, 22.4, 23.8, 25.7, 40.3, 60.7, 108.6, 111.5, 117.5, 
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121.5, 125.1, 128.7, 134.4, 134.8, 175.5. LRMS (ES+) m/z: 316.15 [M+K]+. HRMS (ES+) calcd. 
for C15H17NO2Cl [M+H]+ 278.0948, found 278.0951.     
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid (16) 
General deesterification procedure with 15 (111.8 mg, 0.40 mmol) provided 16 (47.7 mg, 47% 
yield) as a beige powder following trituration with CH2Cl2, mp 178 -180 °C. 1H NMR (MeOD, 500 
MHz): 1.97-1.99 (1H, m), 2.26-2.29 (1H, m), 2.78-2.82 (4H, m,), 2.96 (1H, d, J = 11 Hz), 6.96 
(1H, d, J = 8 Hz), 7.17 (1H, d, J = 8.5 Hz), 7.31 (1H, s), 10.21 (1H, br s). 13C NMR (MeOD, 125 
MHz): 23.1, 24.8, 27.0, 41.5, 108.3, 112.5, 117.6, 121.5, 125.2, 129.9, 136.2, 136.6, 179.4 (C). 
LRMS (ES-) m/z: 247.99 [M-H]-. HRMS (ES-) calcd. for C13H11NO2Cl [M-H]- 248.0478, found 
248.0474. 
Methyl 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate (17) 
General esterification procedure with 16 (43.7 mg, 0.18 mmol) in methanol provided 17 (30.7 
mg, 65% yield) as a pale yellow powder following trituration with petrol, mp 104  - 106 °C. 1H 
NMR (CDCl3, 300 MHz): 1.99-2.05 (1H, m), 2.27-2.31 (1H, m), 2.79-3.01 (5H, m), 3.74 (3H, s), 
7.05 (1H, dd, J = 8.7, 1.5 Hz), 7.14 (1H, d, J = 8.4 Hz), 7.40 (1H, s), 7.84 (1H, br s). 13C NMR 
(CDCl3, 125 MHz): 22.4, 22.8, 25.6, 40.1, 52.0, 108.4, 111.5, 117.5, 121.5, 125.1, 128.7, 134.4, 
134.8, 175.9 (C). LRMS (ES-) m/z: 262.04 [M-H]-. HRMS (ES-) calcd. for C14H13NO2Cl [M-H]- 
262.0635, found 262.0630. 
7-chloro-1,2,3,4-tetrahydrocyclopenta[b]indole (18)10 
General Fischer indole procedure with  4-chlorophenylhydrazine hydrochloride (429.9 mg, 2.40 
mmol) and cyclopentanone (248.4 mg, 2.95 mmol) in glacial acetic acid (4 mL) provided 18 
(46.9 mg, 10 % yield) as beige crystalline solid following FCC on silica (gradient elution; 
30:70:0.5 - 50:50:0.5 Et2O/petrol/acetic acid), mp 124 – 126 °C. 1H NMR (d6-DMSO, 300 MHz): 
2.42-2.47 (2H, m), 2.68-2.73 (2H, m), 2.79-2.84 (2H, m), 6.95 (1H, dd, J = 8.4, 2.1 Hz), 7.26 
(1H, d, J = 8.4 Hz), 7.32 (1H, d, J = 2.1 Hz), 11.05 (1H, s). 13C NMR (d6-DMSO, 125MHz): 23.8, 
25.2, 28.1, 112.8, 117.0, 117.4, 119.2, 123.0, 125.1, 139.3, 146.3. LRMS (ES+) m/z: 192.0 
[M+H]+. HRMS (ES+) calcd. for C11H11NCl [M+H]+ 192.0580, found 192.0587. 
6-chloro-2,3,4,9-tetrahydro-1H-pyrido[2,1-b]indole hydrochloride (19)11 
General Fischer indole procedure with 4-piperidinone hydrate hydrochloride (200.8 mg, 1.31 
mmol) and 4-chlorophenylhydrazine hydrochloride (244.9 mg, 1.37 mmol) in absolute ethanol (2 
mL) provided 19 (43.1 mg, 14% yield) as an off white power following recrystallisation from 
methanol, mp 278 °C (dec.). 1H NMR (MeOD, 300 MHz): 3.16-3.18 (2H, br t), 3.59-3.63 (2H,t), 
4.40 (2H, s), 7.10 (1H, d, J = 8.7 Hz), 7.31 (1H, d, J = 8.4 Hz), 7.45 (1H, s). 13C NMR (MeOD, 
125MHz): 21.4, 42.1, 42.9, 102.6, 113.4, 117.9, 123.1, 126.3, 127.5, 132.8, 136.3.  LRMS (ES+) 
m/z: 207.09 [M+H]+. HRMS (ASAP+) calcd. for C11H12N2Cl [M+H]+ 207.0689, found 207.0698. 
9-chloro-1,2,3,4,5,6-hexahydrocyclohepta[b]indole (20)12 
General Fischer indole procedure with 4-chlorophenylhydrazine hydrochloride (442.8 mg, 2.47 
mmol) and cycloheptanone (300.9 mg, 2.68 mmol) in glacial acetic acid (4 mL) provided 20 
(300.9 mg, 55% yield) as an off-white crystalline solid following recrystallisation from 
ethanol/water, mp 124 – 126 °C. 1H NMR (d6-DMSO, 500 MHz): 1.66-1.68 (4H, m), 1.83 (2H, 
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m), 2.69-2.70 (2H, m), 2.80-2.81 (2H, m), 6.93 (1H, d, J = 8.0 Hz), 7.21 (1H, d, J = 8.5Hz), 7.38 
(1H, s), 10.87 (1H, br s). 13C NMR (d6-DMSO, 125MHz): 24.1, 27.0, 28.4, 28.5, 31.4, 111.8, 
111.9, 116.3, 119.3, 122.7, 129.8, 132.5, 140.1. LRMS (ES+) m/z: 220.1 [M+H]+. HRMS (ES+) 
calcd. for C13H15NCl [M+H]+ 220.0893, found 220.0892. 
Methyl 5-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylate (21) 
General Fischer indole procedure with 3-chlorophenylhydrazine hydrochloride (482.3 mg, 2.69 
mmol) and methyl-2-oxocyclohexane-1-carboxylate (459.7 mg, 2.94 mmol) in glacial acetic acid 
(4 mL) provided 21 (32.9 mg, 5% yield) as a pale yellow oil following FCC on silica gel (1:1:98 
Et2O/EtOAc/petrol). 1H NMR (CDCl3, 300 MHz): 1.82-1.88 (1H, m), 2.02-2.07 (1H, m), 2.15-2.23 
(3H, m), 3.79 (3H, s), 3.87 (1H, t, J = 6.3Hz), 7.00 (1H, t, J = 7.8 Hz), 7.15 (1H, d, J = 7.5 Hz), 
7.37 (1H, d, J = 7.8 Hz), 8.50 (1H, s). 13C NMR (CDCl3, 75 MHz): 20.9, 21.7, 26.1, 39.9, 52.5, 
113.2, 116.4, 117.0, 120.2, 121.4, 128.9, 130.4, 133.3, 172.9. LRMS (ES-) m/z: 262.05 [M-H]-. 
HRMS (ESI-) calcd. for C14H13NO2Cl. 262.0635, found 262.0645.   
8-chloro-2,3,4,9-tetrahydro-1H-carbazole (22)13 
General Fischer indole procedure with 2-chlorophenylhydrazine hydrochloride (258.8 mg, 1.45 
mmol) and cyclohexanone (162.8 mg, 1.66 mmol) in glacial acetic acid (4 mL) provided  22 
(129.4 mg, 43% yield) as a pale yellow oil following FCC on silica gel (1:9 – 2:8 Et2O/petrol). 1H 
NMR (MeOD, 500 MHz): 1.85-1.90 (4H, m) 3.64-2.66 (2H, t like), 2.74-2.76 (2H, t like), 6.89 
(1H, t, J = 7.8 Hz,), 6.98 (1H, d, J = 7.5 Hz), 7.26 (1H, d, J = 8.0 Hz). 13C NMR (MeOD, 
125MHz): 22.0, 24.0, 24.3, 23.5, 111.0, 116.9, 117.0, 120.0, 120.7, 130.9, 134.4, 136.8.  LRMS 
(ES-) m/z: 205 [M-H]-. LRMS (ES-) m/z: 205 [M-H]-. HRMS (ASAP+) calcd. for C12H13NCl [M+H]+ 
206.0737, found 206.0739. 
8-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid (24)14 
General deesterification procedure with 23 (77.0 mg, 0.28 mmol) provided 24 (21.5 mg, 31% 
yield) as an off-white powder following FCC on silica gel (20:80:0.5 EtOAc/petrol/acetic acid), 
mp 196 -198 °C. 1H NMR (MeOD, 500 MHz): 1.97-2.00 (1H, m), 2.27-2.30 (1H, m), 2.78-2.87 
(4H, m,), 2.97-3.01 (1H, m), 6.91 (1H, t, J = 7.8 Hz), 7.01 (1H, d, J = 8.0 Hz), 7.29 (1H, d, J = 
8.0 Hz). 13C NMR (MeOD, 125 MHz): 23.1, 25.0, 27.0, 41.5, 109.3, 117.0, 120.3, 121.0, 130.6, 
134.7, 136.1, 179.4. LRMS (ES-) m/z: 248.15 [M-H]-. HRMS (ES-) calcd. for C13H11NO2Cl [M-H]- 
248.0478, found 248.0477. 
6-chloro-2,3,4,9-tetrahydro-1H-carbazol-7-ol (25) 
General hydrazine formation procedure with 2-chloro-5-aminophenol (1.93 g, 13.45 mmol) 
provided 2-chloro-5-hydrazinylphenol hydrochloride (30; 1.99 mg, 75% yield) as a pinkish 
powder, mp >160 °C (dec.).  1H NMR (d6-DMSO, 500 MHz): 6.42 (1H, dd, J = 8.5, 2.5 Hz), 6.60 
(1H, d, J = 2.0 Hz), 7.20 (1H, d, 8.5 Hz), 8.23 (1H, s), 10.06 (1H, br s), 10.25 (1H, s). LRMS 
(ES+) m/z: 159.04 [M+H]+. 
General Fischer indole procedure with 30 (528.7 mg, 2.71 mmol) and cyclohexanone (285.3 
mg, 2.90 mmol) in absolute ethanol (6 mL) provided 25 (16.7 mg, 8% yield) as a beige powder 
following FCC on silica gel (gradient elution; 1:9-4:6 Et2O/petrol), mp 150 – 152 °C. 1H NMR 
(CDCl3, 500 MHz): 1.84-1.88 (4H, m), 2.60-2.62 (2H, m), 2.65-2.67 (2H, m), 6.90 (1H, s), 7.35 
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(1H, s), 7.54 (1H, s). 13C NMR (CDCl3, 125 MHz): 20.9, 23.2, 23.3, 97.3, 109.8, 113.1, 117.3, 
123.1, 134.3, 135.5, 146.4. LRMS (ES+) m/z: 221.89 [M+H]+. HRMS (ASAP+) calcd. for 
C12H13NOCl [M+H]+ 222.0686, found 222.0676. 
6-chloro-2,3,4,9-tetrahydrocarbazole-2,5-dicarboxylic acid (26) 
General Fischer indole procedure with 2-chloro-5-hydrazinobenzoic acid hydrochloride (32; 
196.5 mg, 0.88 mmol) and 3-oxocyclohexanecarboxylic acid (117.4 mg, 0.83 mmol) in glacial 
acetic acid (2 mL) produced a mixture of two isomers. The desired isomer was separated by 
first methylating the mixture (general esterification procedure), followed by FCC on silica gel 
(40:60:0.5 EtOAc/petrol/acetic acid) to give the mono-methylated 6-chloro-2,3,4,9-
tetrahydrocarbazole-2,5-dicarboxylic acid (48.5 mg), which was demethylated  (general 
deesterification procedure) to give 26 (15.6 mg, 10% yield) as a pale yellow powder, mp 222 – 
224 °C.  1H NMR (MeOD, 500 MHz): 1.89-1.94 (1H, m), 2.24-2.66 (1H, m), 2.66-2.72 (1H, m), 
2.77-2.87 (2H, m), 2.98-3.00 (2H, m), 7.03 (1H, d, J = 8.0 Hz), 7.27 (1H, d, J = 9.0 Hz). 13C 
NMR (CDCl3+MeOD, 125 MHz): 20.4, 25.4, 26.3, 39.6, 107.7, 112.6, 120.4, 121.1, 123.6, 
124.4, 134.9, 135.5, 179.0. LRMS (ES+) m/z: 316.15 [M+Na]+. HRMS (ES+) calcd. for 
C14H12NO4ClNa [M+Na]+  316.0353, found 316.0348. 
7-chloro-1,2,3,4-tetrahydrocyclopenta[b]indole-8-carboxylic acid (27) 
General Fischer indole procedure with 2-chloro-5-hydrazinobenzoic acid hydrochloride (32; 
436.2 mg, 1.96 mmol) and cyclopentanone (139.6 mg, 1.66 mmol) in glacial acetic acid (2 mL) 
provided 27 (11.3 mg, 2% yield) as a yellow powder following FCC on silica gel (30:70:0.5 
EtOAc/petrol/acetic acid) and recrystallisation from methanol/water, mp 208 – 210 °C. 1H NMR 
(d6-DMSO, 300 MHz): 2.40-2.44 (2H, m), 2.68 (2H, br t, J = 6.8 Hz), 2.82 (2H, br t, J = 7.2Hz), 
7.01 (1H, d, J = 9 Hz), 7.34 (1H, dd, J = 8.7, 1.2 Hz), 11.26 (1H, s), 13.17 (1H, s). 13C NMR (d6-
DMSO, 75 MHz): 24.9, 25.2, 28.0, 114.1, 117.2, 120.1, 120.2 (C-H), 122.7 (2xC), 139.5, 147.6, 
167.8. LRMS (ES-) m/z: 234.0 [M-H]-. HRMS (ES-) calcd. for C12H9NO2Cl [M-H]- 234.0322, 
found 234.0320. 
Methyl 6-chloro-2,3,4,9-tetrahydrocarbazole-7-carboxylate (29) 
General Fischer indole procedure with 2-chloro-5-hydrazinobenzoic acid hydrochloride (32; 
364.5 mg, 1.63 mmol) and cyclohexanone (113.3 mg, 1.15 mmol) in glacial acetic acid (4 mL) 
provided 6-chloro-2,3,4,9-tetrahydrocarbazole-7-carboxylic acid (44.4 mg, 16% yield) as a white 
powder following FCC on silica gel (20:80:0.5 EtOAc/petrol/acetic acid). 1H NMR (CDCl3 + d6-
DMSO, 500 MHz): 1.87-1.91 (4H, m), 2.66-2.67 (2H, m), 2.75-2.76 (2H, m), 7.43 (1H, s), 7.98 
(1H, s), 9.79 (1H, s). LRMS (ES+) m/z: 272.2 [M+Na]+. HRMS (ES+) calcd. for C13H13NO2Cl 
[M+H]+ 250.0635, found 250.0657.   
General esterification procedure with 6-chloro-2,3,4,9-tetrahydrocarbazole-7-carboxylic acid 
(36.6 mg, 0.15 mmol) in methanol (1.5 mL) provided 29 (7.0 mg, 18% yield) as a beige powder 
following trituration with CH2Cl2, mp 198 -200 °C. 1H NMR (d6-DMSO, 500 MHz): 1.77-1.83 (4H, 
m), 2.59-2.61 (2H, m), 2.72-2.73 (2H, m), 3.82 (3H, s), 7.46 (1H, s), 7.79 (1H, s), 11.19 (1H, br 
s). 13C NMR (d6-DMSO, 125 MHz): 20.3, 22.4, 22.6, 22.8, 51.9, 108.8, 114.1, 118.8, 119.7, 
121.9, 130.4, 133.2, 140.5, 166.1. LRMS (ES+) m/z: 286.211 [M+Na]+. HRMS (ES+) calcd. for 
C14H15NO2Cl [M+H]+ 264.0791, found 264.0800. 
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